Latest & greatest articles for infection

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infection or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infection and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infection

3641. Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection.

Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. 2508850 1989 12 08 1989 12 08 2013 10 02 0959-8138 299 6700 1989 Sep 09 BMJ (Clinical research ed.) BMJ Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. 652-6 To confirm the findings of pilot studies that interferon alfa is an effective treatment of Europid men with chronic hepatitis B virus infection (...) of 100% and a specificity of 80%. Four of the 12 responders, who had all been infected for less than two years, also lost hepatitis B surface antigen. Treatment was well tolerated. Interferon alfa is effective in the treatment of a proportion of Europid men with chronic hepatitis B virus infection, who might be identified before treatment. Additional strategies are required to improve the rate of response. Brook M G MG Academic Department of Medicine, St Mary's Hospital Medical School, London. Chan G

BMJ1989 Full Text: Link to full Text with Trip Pro

3642. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group.

Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. 2566781 1989 07 03 1989 07 03 2015 06 16 0140-6736 1 8649 1989 Jun 03 Lancet (London, England) Lancet Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. 1228-31 A multicentre, controlled trial was carried out to determine (...) whether removal of leucocytes from blood by means of 'Imugard IG500' (Terumo) filters would prevent transfusion-acquired cytomegalovirus (CMV) infection in newborn infants. 72 infants whose mothers were seronegative and who received some seropositive blood were followed for 6 months for evidence of CMV infection. There were no significant differences between the groups who received filtered and unfiltered blood in median gestation, birthweight, or amount of seropositive blood received (median volume

Lancet1989

3643. Different lengths of treatment with co-trimoxazole for acute uncomplicated urinary tract infections in women.

Different lengths of treatment with co-trimoxazole for acute uncomplicated urinary tract infections in women. 2513939 1990 02 22 1990 02 22 2015 11 19 0959-8138 299 6711 1989 Nov 25 BMJ (Clinical research ed.) BMJ Different lengths of treatment with co-trimoxazole for acute uncomplicated urinary tract infections in women. 1319-22 To compare three days' and seven days' treatment with co-trimoxazole in women with acute dysuria, strangury, and urinary frequency or urgency. Randomised double blind (...) ' and seven days' treatment were 31/139 (22%) and 23/151 (15%) respectively six weeks after entry (p = 0.16). Adverse effects occurred in a quarter of women given three days' treatment compared with a third of women receiving seven days' treatment (p = 0.29). In only two patients did adverse effects necessitate stopping treatment. Three days of co-trimoxazole seems to be as effective as a seven days' course for treating acute urinary tract infection in non-pregnant women. Trienekens T A TA Department

BMJ1989 Full Text: Link to full Text with Trip Pro

3644. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection.

Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. 2899719 1988 09 02 1988 09 02 2015 06 16 0140-6736 2 8606 1988 Aug 06 Lancet (London, England) Lancet Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. 298-302 72 Chinese patients who had been positive for hepatitis B surface antigen (HBsAg) and hepatitis B e (...) of HBV replication subsequently occurred in 7 (13%) of the treated patients and in 1 control. Thus, sustained clearance of HBeAg was achieved only in 8 (15%) of treated patients at 12 months. Between 12 and 24 months 3 (9%) of treated patients and 1 control became negative for HBeAg. None of the patients became HBsAg-negative. alpha 2-interferon in the dose regimen used has little long-term effect in the suppression of HBV replication in Chinese patients with chronic HBV infection. Lok A S

Lancet1988

3645. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia.

Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. 2901668 1988 10 24 1988 10 24 2007 11 15 0028-4793 319 14 1988 Oct 06 The New England journal of medicine N. Engl. J. Med. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group (...) for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. 902-7 In a double-blind study, we randomly assigned 84 patients with chronic lymphocytic leukemia who were judged to be at increased risk of bacterial infection to receive intravenous immunoglobulin G (400 mg per kilogram of body weight) or a placebo every three weeks for one year. Eligible patients had hypogammaglobulinemia, a history of infection, or both. The patients receiving immunoglobulin had significantly fewer bacterial infections

NEJM1988

3646. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial.

Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. 3290517 1988 07 29 1988 07 29 2016 10 17 0098-7484 260 2 1988 Jul 08 JAMA JAMA Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. 201-6 Normal adults with six or more episodes of genital herpes in the previous year were enrolled in a one-year, multicenter, double-blind trial comparing

JAMA1988

3647. Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections.

Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. 2897559 1988 07 08 1988 07 08 2015 06 16 0140-6736 1 8598 1988 Jun 11 Lancet (London, England) Lancet Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. 1305-9 To compare the efficacy of once daily monotherapy with that of standard combination antibiotic therapy for the initial management of patients suspected (...) of serious bacterial infections, 105 patients were randomised to treatment with ceftriaxone alone (53 patients) or to a combination of cefuroxime and gentamicin (52 patients). There was no difference between the groups in proportions responding to therapy or proportions dying from infection, except when non-evaluable patients were excluded from the group with definite bacterial infection, in which case response was better among those treated with ceftriaxone. The groups did not differ in number of side

Lancet1988

3648. Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('Imuthiol') in human immunodeficiency virus infection.

Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('Imuthiol') in human immunodeficiency virus infection. 2901566 1988 10 21 1988 10 21 2015 06 16 0140-6736 2 8613 1988 Sep 24 Lancet (London, England) Lancet Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('Imuthiol') in human immunodeficiency virus infection. 702-6 83 patients with human immunodeficiency virus (HIV) infection (CDC groups II, III, or IV-A) were randomised in a crossover trial

Lancet1988

3649. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy.

Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. 3184334 1988 12 07 1988 12 07 2016 10 17 0098-7484 260 18 1988 Nov 11 JAMA JAMA Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. 2682-5 We conducted a double-blind, controlled trial of low-dose (150 mg/d) oral clindamycin hydrochloride vs placebo to prevent recurrent staphylococcal skin infections. Twenty-two patients (11 in both the placebo (...) and clindamycin treatment groups) completed the trial and were assessable. The two groups did not differ as to age, sex, race, or the number of recurrent abscesses preceding the trial. In pretrial evaluations, no patient had hypogammaglobulinemia or abnormal neutrophil function. Sixty-four percent (7/11) of the placebo-treated patients had a recurrent abscess within three months of enrollment whereas 82% (9/11) of the patients treated with clindamycin were free of any infection during the three-month

JAMA1988

3650. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation.

Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Intravenous immune globulin for p... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1987 ) Volume: 106 , Issue: 1 , Pages: 12-18 PubMed: Available from or Find this paper at: Abstract The effects of high doses of polyvalent intravenous immune globulin (...) given for prophylaxis of cytomegalovirus infection and interstitial pneumonia in recipients of allogeneic marrow transplants were evaluated in a randomized controlled trial. Both symptomatic cytomegalovirus infection (21% compared with 46%, p = 0.03) and interstitial pneumonia (18% compared with 46%, p = 0.02) occurred less frequently in the recipients of intravenous immune globulin than in control patients. Prophylactic intravenous immune globulin was also associated with a lower incidence of graft

Annals of Internal Medicine1987

3651. Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection

Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection Hay J W, Daum R S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) . This makes the baseline findings speculative. 4) The parameters investigated by sensitivity analysis and the ranges of values were not adequately justified. 5) Vaccine side-effects were considered in the sensitivity analysis. Bibliographic details Hay J W, Daum R S. Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection. Pediatrics 1987; 80(3): 319-329 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adult; Age Factors; Bacterial

NHS Economic Evaluation Database.1987

3652. Evaluation of dressing regimens for prevention of infection with peripheral intravenous catheters. Gauze, a transparent polyurethane dressing, and an iodophor-transparent dressing.

Evaluation of dressing regimens for prevention of infection with peripheral intravenous catheters. Gauze, a transparent polyurethane dressing, and an iodophor-transparent dressing. 3118061 1987 11 24 1987 11 24 2016 10 17 0098-7484 258 17 1987 Nov 06 JAMA JAMA Evaluation of dressing regimens for prevention of infection with peripheral intravenous catheters. Gauze, a transparent polyurethane dressing, and an iodophor-transparent dressing. 2396-403 Four dressing regimens for peripheral venous (...) and comparable with all four dressings (range, 10(0.58) to 10(0.70) colony-forming units). The rate of local catheter-related infection (greater than or equal to 15 colony-forming units) was also low and did not differ significantly (range, 4.6% to 5.9%); no catheter caused bacteremia. Stepwise logistic multivariate analysis showed cutaneous colonization of the insertion site (relative risk [RR] of infection, 3.86), contamination of the catheter hub (RR, 3.78), moisture under the dressing (RR, 2.48

JAMA1987

3653. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.

Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. 2880066 1987 03 04 1987 03 04 2015 06 16 0140-6736 1 8527 1987 Jan 31 Lancet (London, England) Lancet Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. 235-7 40 adult patients with cystic fibrosis (CF) were admitted to hospital with acute exacerbations of infection (...) for patients with CF who are infected with Ps aeruginosa. Hodson M E ME Roberts C M CM Butland R J RJ Smith M J MJ Batten J C JC eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Gentamicins 5E8K9I0O4U Ciprofloxacin HUM6H389W0 Azlocillin AIM IM Acute Disease Administration, Oral Adolescent Adult Azlocillin administration & dosage Ciprofloxacin administration & dosage Clinical Trials as Topic Cystic Fibrosis complications physiopathology

Lancet1987

3654. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections.

Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. 2882184 1987 05 14 1987 05 14 2015 06 16 0140-6736 1 8536 1987 Apr 04 Lancet (London, England) Lancet Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. 774-6 To study the importance of transferred immunity against cytomegalovirus (CMV) in allogeneic, HLA-matched, T-cell-depleted bone-marrow transplantation, the incidence, severity, and outcome of CMV (...) infections were studied in 40 CMV-seropositive recipients in relation to the donors' immunity against CMV. There was no significant difference in the incidence of CMV infections between recipients of seropositive (n = 27) and seronegative (n = 13) marrow. However, the incidence of CMV pneumonitis (8/13 compared with 4/27; p less than 0.001) and the mortality attributable to CMV infection (6/13 compared with 1/27, p less than 0.01) were significantly greater in the group with seronegative donors than

Lancet1987

3655. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection.

Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. 2885573 1987 08 12 1987 08 12 2015 06 16 0140-6736 2 8550 1987 Jul 11 Lancet (London, England) Lancet Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. 66-9 46 male chronic hepatitis B virus (HBV) carriers with active viral replication were randomised, with stratification for histology and sexual preference, to receive six months' lymphoblastoid interferon or no therapy. After nine

Lancet1987

3656. Effect of the contraceptive sponge on chlamydial infection, gonorrhea, and candidiasis. A comparative clinical trial.

Effect of the contraceptive sponge on chlamydial infection, gonorrhea, and candidiasis. A comparative clinical trial. 3033339 1987 05 22 1987 05 22 2016 11 23 0098-7484 257 17 1987 May 01 JAMA JAMA Effect of the contraceptive sponge on chlamydial infection, gonorrhea, and candidiasis. A comparative clinical trial. 2308-12 To investigate the effect of the nonoxynol 9-impregnated contraceptive sponge on the incidence of chlamydial infection, gonorrhea, and candidiasis, we conducted a randomized (...) comparative study among high-risk women in Bangkok, Thailand. The first (parallel) portion of the study covered 434 woman-weeks among sponge users and 494 woman-weeks among nonusers. As compared with women not using the sponge, sponge users were found to be less likely to become infected with chlamydia (relative rate, 0.67; 95% confidence interval, 0.42 to 1.07) and gonorrhea (relative rate, 0.31 [0.16 to 0.60]) but more likely to become infected with Candida (relative rate, 2.76 [0.96 to 7.98]). Women

JAMA1987

3657. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin.

Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. 2442610 1987 10 22 1987 10 22 2007 11 14 0028-4793 317 15 1987 Oct 08 The New England journal of medicine N. Engl. J. Med. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. 923-9 Apache Indian infants have a high frequency of Haemophilus influenzae type b (Hib) and pneumococcal (...) infections. Forty percent of Hib infections in these infants occur before the age of six months, when active immunization may not be protective. To evaluate the efficacy of passive immunization with a human hyperimmune globulin (bacterial polysaccharide immune globulin [BPIG]) prepared from the plasma of immunized adult donors, we randomly assigned 703 infants in a double-blind fashion to receive 0.5 ml of BPIG per kilogram of body weight (n = 353) or 0.5 ml of saline (n = 350) intramuscularly at 2, 6

NEJM1987

3658. Controlled trial of 'InterVir-A' in herpes simplex virus infection.

Controlled trial of 'InterVir-A' in herpes simplex virus infection. 2870223 1986 04 25 1986 04 25 2015 11 19 0140-6736 1 8483 1986 Mar 29 Lancet (London, England) Lancet Controlled trial of 'InterVir-A' in herpes simplex virus infection. 703-6 'InterVir-A' (IVA), an agent with in-vitro anti herpes-simplex-virus (HSV) activity was compared with a placebo (PBO) in the treatment of recurrent perianal, orofacial, and genital HSV I and II infection in a randomised double-blind trial. Samples from

Lancet1986

3659. A scoring method (ASEPSIS) for postoperative wound infections for use in clinical trials of antibiotic prophylaxis.

A scoring method (ASEPSIS) for postoperative wound infections for use in clinical trials of antibiotic prophylaxis. 2868173 1986 03 13 1986 03 13 2015 06 16 0140-6736 1 8476 1986 Feb 08 Lancet (London, England) Lancet A scoring method (ASEPSIS) for postoperative wound infections for use in clinical trials of antibiotic prophylaxis. 311-3 To compare antibiotic regimens for their effectiveness in preventing or treating wound sepsis, well-defined criteria for outcome are needed. A method (...) Surgical Wound Infection diagnosis microbiology prevention & control Teicoplanin Time Factors 1986 2 8 1986 2 8 0 1 1986 2 8 0 0 ppublish 2868173 S0140-6736(86)90838-X

Lancet1986

3660. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation.

Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. 3007984 1986 05 06 1986 05 06 2016 04 22 0028-4793 314 16 1986 Apr 17 The New England journal of medicine N. Engl. J. Med. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. 1006-10 In an attempt to prevent primary cytomegalovirus infection after marrow transplantation (...) of cytomegalovirus infection according to study group among patients in the study for at least 62 days was 5 percent, 13 percent, 24 percent, and 40 percent, respectively. Among 57 patients with seronegative marrow donors, those who received seronegative blood products had significantly less infection (1 of 32) than those who received standard blood products (8 of 25, P less than 0.007). In contrast, the use of seronegative blood products did not appear to prevent cytomegalovirus infection among patients

NEJM1986